Abstract
Only rarely in modern medicine is an entirely new class of drug developed. Recently, a number of drugs that act as leukotriene modifiers (LTMs) have been licensed for use in the treatment of asthma. Airway obstruction in asthma has two key components-bronchoconstriction of airway smooth muscle and airway inflammation. Although a number of mediators are involved in this process, it has been demonstrated that leukotrienes can precipitate both. Leukotrienes are formed in eosinophils, mast cells and neutrophils. LTMs have been shown to attenuate bronchial hyper-reactivity and reduce chemotaxis of inflammatory cells in the asthmatic airway. This article reviews the data from clinical trials of LTMs, discusses their role in asthma therapy and postulates on use in other common respiratory diseases.
Keywords: Leukotriene Modifying Drugs, Asthma, Bronchoconstriction, Leukotrienes, Airway Inflammation, Cystic Fibrosis
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Anti-Obesity Drug Discovery and Development
1